Literature DB >> 26453806

Polymeric oncolytic adenovirus for cancer gene therapy.

Joung-Woo Choi1, Young Sook Lee1, Chae-Ok Yun2, Sung Wan Kim1.   

Abstract

Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Cancer gene therapy; Clinical trials; Oncolytic Ad/polymer hybrid vector; Oncolytic adenovirus; Systemic administration; Tumor microenvironment targeting

Mesh：

Substances：

Year:  2015        PMID： 26453806      PMCID： PMC4668934          DOI： 10.1016/j.jconrel.2015.10.009

Source DB:  PubMed          Journal:  J Control Release        ISSN： 0168-3659            Impact factor:   9.776


  125 in total

Review 1.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Authors:  Devika Gajria; Sarat Chandarlapaty
Journal:  Expert Rev Anticancer Ther       Date:  2011-02       Impact factor: 4.512

2.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

3.  Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.

Authors:  Jaesung Kim; Yi Li; Sung Wan Kim; Doo Sung Lee; Chae-Ok Yun
Journal:  Biomaterials       Date:  2013-03-27       Impact factor: 12.479

4.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

5.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Authors:  T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

6.  Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner.

Authors:  Eunhee Kim; Joo-Hang Kim; Ha-Youn Shin; Hansaem Lee; Jai Myung Yang; Jungho Kim; Joo-Hyuk Sohn; Hoguen Kim; Chae-Ok Yun
Journal:  Hum Gene Ther       Date:  2003-10-10       Impact factor: 5.695

Review 7.  Recombinant viral vaccines for cancer.

Authors:  Ryan Cawood; Thomas Hills; Suet Ling Wong; Aliaa A Alamoudi; Storm Beadle; Kerry D Fisher; Leonard W Seymour
Journal:  Trends Mol Med       Date:  2012-08-21       Impact factor: 11.951

8.  Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Ming Yang; Gregory Christoforidis; Giulia Fulci; Fred H Hochberg; Ralph Weissleder; William Carson; E Antonio Chiocca; Balveen Kaur
Journal:  J Natl Cancer Inst       Date:  2007-11-27       Impact factor: 13.506

9.  Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer.

Authors:  Svend O Freytag; Hans Stricker; Mei Lu; Mohamed Elshaikh; Ibrahim Aref; Deepak Pradhan; Kenneth Levin; Jae Ho Kim; James Peabody; Farzan Siddiqui; Kenneth Barton; Jan Pegg; Yingshu Zhang; Jingfang Cheng; Nancy Oja-Tebbe; Renee Bourgeois; Nilesh Gupta; Zhaoli Lane; Ron Rodriguez; Theodore DeWeese; Benjamin Movsas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-05       Impact factor: 7.038

10.  Systemic delivery of oncolytic viruses: hopes and hurdles.

Authors:  Mark S Ferguson; Nicholas R Lemoine; Yaohe Wang
Journal:  Adv Virol       Date:  2012-01-31
View more
  16 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.

Authors:  Sung Jin Kim; Ju Hyun Kim; Bitna Yang; Jin-Sook Jeong; Seong-Wook Lee
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

3.  Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.

Authors:  Youjin Na; Joung-Pyo Nam; JinWoo Hong; Eonju Oh; Ha Cheol Shin; Hyun Soo Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  J Control Release       Date:  2019-05-06       Impact factor: 9.776

4.  Steering the Clinical Translation of Delivery Systems for Drugs and Health Products.

Authors:  Rosario Pignatello; Pietro Matricardi
Journal:  Pharmaceutics       Date:  2020-04-13       Impact factor: 6.321

5.  "Double-punch" strategy for delivery of viral immunotherapy with prolonged tumor retention and enhanced transfection efficacy.

Authors:  Juan Wang; Chunqing Guo; Xiang-Yang Wang; Hu Yang
Journal:  J Control Release       Date:  2020-12-02       Impact factor: 9.776

Review 6.  Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.

Authors:  Raquel Yokoda; Bolni M Nagalo; Brent Vernon; Rahmi Oklu; Hassan Albadawi; Thomas T DeLeon; Yumei Zhou; Jan B Egan; Dan G Duda; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2017-11-08

Review 7.  Recent advances in the development of gene delivery systems.

Authors:  Y K Sung; S W Kim
Journal:  Biomater Res       Date:  2019-03-12

8.  Synergistic Anti-tumour Effects of Quercetin and Oncolytic Adenovirus expressing TRAIL in Human Hepatocellular Carcinoma.

Authors:  Hai Zou; Yong-Fa Zheng; Wei Ge; Shi-Bing Wang; Xiao-Zhou Mou
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

9.  Targeting Melanoma with Cancer-Killing Viruses.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Helene M Woyczesczyk; Karim Essani
Journal:  Open Virol J       Date:  2017-03-31

Review 10.  Oncolytic Adenovirus-A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC.

Authors:  Mubalake Abudoureyimu; Yongting Lai; Chuan Tian; Ting Wang; Rui Wang; Xiaoyuan Chu
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.